Suven Life Sciences, a biopharmaceutical company specializing in drug discovery and developmental activities in central nervous system disorders reported net profit flat at Rs 247.29 million for the quarter ended September 2015 from Rs 248.36 million in the same quarter previous year.
Revenues for the quarter declined 16.50% to Rs 1,167.61 million from Rs 1,398.31 million in the same period last year. On sequential basis, the revenues rose 15.63% from Rs 1,010 million in the previous quarter of this fiscal.
Operating margin for the quarter stood at 26.32 percent as compared to 35.55 percent for the previous year period. Operating Income for the quarter was Rs 307.33 million, compared with Rs 359.02 million in the previous year period.
Earnings per share for the quarter stood at Rs 1.94, registering 8.92% decline over previous year period.
| Quarterly Results - Consolidated (Rs in mn) |
| As at | Sep - 15 | Sep - 14 | %Change |
| Revenues | 1,167.61 | 1,009.81 | 15.63 |
| Net Profit | 247.29 | 248.36 | (0.43) |
| Diluted EPS | 1.94 | 2.13 | (8.92) |
Shares of the company gained Rs 2.3, or 0.88%, to trade at Rs 264.40. The total volume of shares traded was 198,211 at the BSE (2.33 p.m., Tuesday).
